```
* * * * * * * * * * *   Welcome to STN International   * * * * * * * * * * *
* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:52:58 ON 15 APR 2008

=> file reg
=>  Uploading C:\Program Files\Stnexp\Queries\Queries\10554187.str
```




```
chain nodes :
21
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18
ring/chain nodes :
20
chain bonds :
5-14  6-9  20-21
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12  13-14  13-18  14-
15  15-16  16-17  17-18
exact/norm bonds :
20-21
exact bonds :
5-14  6-9
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12  13-14  13-18  14-
15  15-16  16-17  17-18
isolated ring systems :
containing 1 : 7 : 13 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  20:CLASS
21:CLASS  22:Atom


=> s l1 sam
L2            1 SEA SSS SAM L1
```

```
=> s l1 full
L3           36 SEA SSS FUL L1

=> file caplus

=> s l3
L4            5 L3

=> s l4 and pd< april 2003
      23709103 PD< APRIL 2003
                 (PD<20030400)
L5            0 L4 AND PD< APRIL 2003

=> dis l4 1-5 bib abs fhitstr

L4   ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2007:754778  CAPLUS  Full-text
DN   147:158512
TI   Pharmaceutical compositions containing substituted phenyl- or
     heteroaryl-substituted pyridines or pyrimidines
IN   Hirai, Miki; Kusama, Mari; Hosaka, Toshihiro; Komi, Shuntaro
PA   Tanabe Seiyaku Co., Ltd., Japan
SO   Jpn. Kokai Tokkyo Koho, 41pp.
     CODEN: JKXXAF
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   JP 2007176933        A     20070712    JP 2006-320941         20061129
PRAI JP 2005-343013       A     20051129
OS   MARPAT 147:158512
GI
```



I

```
AB   Substituted pyridines or pyrimidines I [ring Q indicates pyridine or
     pyrimidine; ring A indicates benzene or heteroarom. ring; G = (un)substituted
     benzene, (un)substituted heterocycle, (un)substituted cycloalkane,
     (un)substituted cycloalkene, (un)substituted amino; R1 = amido, hydrazido,
     hydroxamic acid residue, ester group, cyano, etc.; R2, R3 = cyano, NO2, etc.;
     m, n = 0-2; R4 = H, halo, etc.; R5, R6 = H, (un)substituted alkyl, etc.] or
     their salts are useful as high-conductance Ca-sensitive K channel openers for
     pharmaceutical compns. for prevention and/or treatment of urinary frequency,
     urinary incontinence, asthma, or chronic obstructive pulmonary disease (COPD).
     2-(2-Methylpyridin-5-yl)-3- (4-aminocarbonyl)phenyl-5-chloropyridine
     (preparation given) inhibited the KCl-induced contraction of rabbit bladder
     with IC50 of 0.5-1 μM.
IT   870723-07-2P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
```

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted phenyl- or heteroaryl-substituted pyridines or pyrimidines as high-conductance Ca-sensitive K channel openers for pharmaceutical compns.)

RN 870723-07-2 CAPLUS

CN Benzamide, N-[(5-methyl-2-pyrazinyl)methyl]-4-(3-phenyl-2-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)



L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1288063 CAPLUS Full-text

DN 144:36364

TI Bicyclic compounds

IN Hirai, Miki; Kusama, Mari; Hosaka, Toshihiro; Kohnomi, Shuntarou

PA Tanabe Seiyaku Co., Ltd., Japan

SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005115984	A2	20051208	WO 2005-JP10287	20050530
	WO 2005115984	A3	20060302		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1771418	A2	20070411	EP 2005-745982	20050530
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2008500951	T	20080117	JP 2006-519585	20050530
	US 20070185116	A1	20070809	US 2006-597890	20061129
PRAI	JP 2004-160660	A	20040531		
	JP 2004-191849	A	20040629		
	US 2004-584142P	P	20040701		
	JP 2004-348136	A	20041201		
	WO 2005-JP10287	W	20050530		

OS MARPAT 144:36364
GI



I



II



III

AB Heterocyclic compds. I [Q = pyridine or pyrimidine; A = benzene or heteroarom. ring; G = ring B optionally substituted with R3, or amino optionally substituted by one or two selected from the group consisting of alkyl, aralkyl and cycloalkyl; ring B = benzene, heterocyclic ring, cycloalkane or cycloalkene; R1 = CON(R6)R5, CON(R6)OR5, CONHN(R6)R5, COON(R6)COR5, CON(R6)SO2R5, COR5, CO2R5, CN; R2 and R3 may be the same or different from each other, and each = CN, NO2, OH, alkoxy, halo, carboxyl, etc.; m = 0, 1 or 2; R4 = H, CN, OH, halo, alkoxy, carbamoyl, etc.; R5 and R6 may be the same or different from each other, and each = H, an optionally substituted alkyl, cycloalkyl, aryl, heterocyclic, alkoxycarbonyl, or R5 and R6 may form an optionally substituted heterocyclic ring in combination with atoms to which they are bonded] and pharmaceutically acceptable salt were prepared as calcium-activated K channel opener useful for treatment of pollakiuria, urinary incontinence, chronic obstructive lung disease and prophylaxis. Thus, compound II was prepared via heterocyclization reaction of III with Vilsmeier agent, and showed a relaxation effect on K-induced contraction of isolated urinary bladder.

IT 870723-07-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as calcium-activated K channel opener for treatment of pollakiuria, urinary incontinence, chronic obstructive lung disease and prophylaxis)

RN 870723-07-2 CAPLUS
CN Benzamide, N-[(5-methyl-2-pyrazinyl)methyl]-4-(3-phenyl-2-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:86368 CAPLUS Full-text
DN 142:211437
TI Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors
AU Zhao, Zhijian; Leister, William H.; Robinson, Ronald G.; Barnett, Stanley F.; Defeo-Jones, Deborah; Jones, Raymond E.; Hartman, George D.; Huff, Joel R.; Huber, Hans E.; Duggan, Mark E.; Lindsley, Craig W.
CS Department of Medicinal Chemistry, Technology Enabled Synthesis Group, Merck Research Laboratories, Merck & Co., West Point, PA, 19486, USA
SO Bioorganic & Medicinal Chemistry Letters (2005), 15(4), 905-909
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 142:211437
AB This letter describes the discovery of a novel series of dual Akt1/Akt2 kinase inhibitors, based on a 2,3,5-trisubstituted pyridine scaffold. Compds. from this series, which contain a 5-tetrazolyl moiety, exhibit more potent inhibition of Akt2 than Akt1.
IT 790659-59-5P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,3,5-trisubstituted pyridine derivs. as potent Akt1/Akt2 dual inhibitors)
RN 790659-59-5 CAPLUS
CN 3-Pyridinecarbonitrile, 5-phenyl-6-[4-[[[[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]methyl]phenyl]- (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:964999 CAPLUS Full-text
DN 141:406038
TI Substituted pyridine compounds as inhibitors of protein kinase Akt activity for treating cancer
IN Duggan, Mark E.; Lindsley, Craig W.; Wu, Zhicai; Zhao, Zhijian; Hartnett,

John C.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004096135	A2	20041111	WO 2004-US12265	20040420
	WO 2004096135	A3	20050324		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004233835	A1	20041111	AU 2004-233835	20040420
	CA 2522435	A1	20041111	CA 2004-2522435	20040420
	EP 1631548	A2	20060308	EP 2004-750420	20040420
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1809536	A	20060726	CN 2004-80017036	20040420
	JP 2006524257	T	20061026	JP 2006-513183	20040420
	US 20060270673	A1	20061130	US 2005-554187	20051021
	IN 2005DN05183	A	20071019	IN 2005-DN5183	20051110
PRAI	US 2003-465125P	P	20030424		
	WO 2004-US12265	W	20040420		

OS MARPAT 141:406038

AB The present invention is directed to compds. which contain a substituted pyridine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compns. containing the compds. of this invention and methods for treating cancer comprising administration of the compds. of the invention.

IT 790659-74-4P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(substituted pyridine compds. as inhibitors of protein kinase Akt activity for treating cancer)

RN 790659-74-4 CAPLUS
CN 3-Pyridinecarbonitrile, 5-phenyl-6-[4-[[[[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]methyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 790659-59-5
CMF C28 H21 N5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:737516 CAPLUS Full-text
DN 139:257284
TI Cathepsin cysteine protease inhibitors and their therapeutic use
IN Bayly, Christopher I.; Black, Cameron; Leger, Serge; Li, Chun Sing; McKay, Dan; Mellon, Christophe; Gauthier, Jacques Yves; Lau, Cheuk; Therien, Michel; Truong, Vouy-Linh; Green, Michael J.; Hirschbein, Bernard L.; Janc, James W.; Palmer, James T.; Baskaran, Chitra
PA Merck Frosst Canada & Co., Can.; Axys Pharmaceuticals, Inc.
SO PCT Int. Appl., 282 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003075836	A2	20030918	WO 2003-US6147	20030228
	WO 2003075836	A3	20040715		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2477657	A1	20030918	CA 2003-2477657	20030228
	AU 2003219953	A1	20030922	AU 2003-219953	20030228
	AU 2003219953	B2	20071101		
	US 20030232863	A1	20031218	US 2003-377377	20030228
	EP 1482924	A2	20041208	EP 2003-716238	20030228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003008208	A	20050111	BR 2003-8208	20030228
	CN 1638757	A	20050713	CN 2003-805181	20030228

	JP 2005526753	T	20050908	JP 2003-574112	20030228
	NZ 534583	A	20061130	NZ 2003-534583	20030228
	RU 2312861	C2	20071220	RU 2004-129587	20030228
	ZA 2004006293	A	20060726	ZA 2004-6293	20040806
	US 20050240023	A1	20051027	US 2004-505796	20040825
	IN 2004CN01940	A	20070720	IN 2004-CN1940	20040831
	MX 2004PA08621	A	20041206	MX 2004-PA8621	20040903
	NO 2004004207	A	20041124	NO 2004-4207	20041004
PRAI	US 2002-361818P	P	20020305		
	US 2002-408704P	P	20020906		
	WO 2003-US6147	W	20030228		

OS MARPAT 139:257284

AB This invention relates to cysteine protease inhibitors R7(D)nCR6R7NR8CR3R4C(:O)NHCR1R2CN (R1-4 = H, (substituted)C1-6-alkyl or C2-6-alkenyl; R1 and R2 or R3 and R4 may be take together with the C atom to which they are attached to form a (substituted)C3-8-cycloalkyl or heterocyclic ring; R5 = H, (substituted)C1-6-alkyl; R6 = (substituted)aryl, heteroaryl, C1-6-haloalkyl, arylalky, heteroarylalkyl; D = (substituted)C1-3-alkyl, C2-3-alkenyl, C2-3-alkynyl, aryl, heteroaryl, C3-8-cycloalkyl, heterocyclyl; R7 = H, (substituted)C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkyloxy, etc.; R8 = H, C2-6-alkyl) including but not limited to, inhibitors of cathepsins K, L, S and B. These compds. are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

IT 603140-97-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(cathepsin cysteine protease inhibitors and their therapeutic use)

RN 603140-97-2 CAPLUS

CN Pentanamide, 2-[[(1S)-1-[4-[5-chloro-3-[4-(methylsulfonyl)phenyl]-2-pyridinyl]phenyl]-2,2,2-trifluoroethyl]amino]-N-(cyanomethyl)-4-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



=> log y

STN INTERNATIONAL LOGOFF AT 11:54:29 ON 15 APR 2008